IL33 and age-related macular degeneration: Together, evidence suggests IL-33 treatment early in AMD may protect RPE, promote metabolic and autophagic homeostasis, and modulate infiltrating cells, resolving pathogenic immune dysregulation and angiogenesis (Fig. 3).